Alpha-1 and 1 for All: Evaluating the Role of Midodrine for Vasopressor Discontinuation

<p>Natalie Haddad, Pharm.D. (<a href='https://twitter.com/NatalieHaddadRx'>@NatalieHaddadRx</a>) explains the mechanism of action of midodrine, reviews the current evidence for midodrine and its impact on vasopressor discontinuation and identifies midodrine’s role in therapy for vasopressor discontinuation.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>